The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy

Cancer and Metastasis Reviews

Volumn 33, Issue 1, 2014, Pages 173-181

  Wang, Hai ^a   Du, Yu Chen ^b,e   Zhou, Xiao Jun ^a   Liu, Hong ^c   Tang, Shou Ching ^c,d  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b Arizona State University   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e SICHUAN CANCER HOSPITAL   (China)

Author keywords

Solid tumors; Survival and targeted therapy; Tumor suppressor and oncogene; YAP 1

Indexed keywords

PROTEIN P73; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN 1; ONCOPROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

BREAST CANCER; CANCER INHIBITION; CANCER PROGNOSIS; CANCER TISSUE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; APOPTOSIS; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, GENETIC; NEOPLASM METASTASIS; NEOPLASMS; ONCOGENE PROTEINS; PHOSPHOPROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84899924908     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9463-3     Document Type: Review

References (77)

1. Zhao, B., et al. (2013). The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nature Cell Biology, 13, 877-883.
2. Zhou, D., et al. (2011). Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proceedings of the National Academy of Sciences of the United States of America, 108, E1312-E1320.
3. Tamm, C., et al. (2011). Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. Journal of Cell Science, 124, 1136-1144.
4. Zhang, H., et al. (2011). Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proceedings of the National Academy of Sciences of the United States of America, 108, 2270-2275.
5. Yu, F. X., et al. (2012). Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell, 150(4), 780-791.
6. Zhao, B., et al. (2007). Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes and Development, 21, 2747-2761.
7. Lapi, E., et al. (2008). PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Molecular Cell, 32, 803-814.
8. Strano, S., et al. (2007). The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Molecular Cell, 18, 447-459.
9. Yuan, M., et al. (2008). Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death and Differentiation, 15, 1752-1759.
10. Bertini, E. (2009). YAP: at the crossroad between transformation and tumor suppression. Cell Cycle, 8, 49-57.
11. Zender, L., et al. (2006). Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell, 125, 1253-1267.
12. Overholtzer, M., et al. (2006). Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proceedings of the National Academy of Sciences of the United States of America, 103, 12405-12410.
13. Zhao, B., et al. (2008). TEAD mediates YAP-dependent gene induction and growth control. Genes and Development, 22, 1962-1971.
14. Barry, E. R., et al. (2013). Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature, 493, 106-110.
15. Hao, Y., et al. (2008). Tumor suppressor LATS1 is a negative regulator of oncogene YAP. Journal of Biological Chemistry, 283, 5496-5509.
16. Oka, T., et al. (2008). Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). Journal of Biological Chemistry, 283, 27534-27546.
17. Ren, F. L., et al. (2010). Hippo signaling regulates Yorkie nuclear localization and activity through 14-3-3 dependent and independent mechanisms. Developmental Biology, 337, 303-312.
18. Zhao, B., et al. (2010). A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes and Development, 24, 72-85.
19. Basu, S., et al. (2003). Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Molecular Cell, 11, 11-23.
20. Zhao, B., et al. (2011). Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes and Development, 25, 51-63.
21. Oka, T., et al. (2010). Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. The Biochemical Journal, 432, 461-472.
22. Remue, E., et al. (2010). TAZ interacts with zonula occludens-1 and -2 proteins in a PDZ-1 dependent manner. FEBS Letters, 584, 4175-4180.
23. Wu, S., et al. (2003). Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell, 114, 445-456.
24. Harvey, K. F., et al. (2003). The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell, 114, 457-467.
25. Callus, B. A., et al. (2006). Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. The FEBS Journal, 273, 4264-4276.
26. Chan, E. H., et al. (2005). Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene, 24, 2076-2086.
27. Praskova, M., et al. (2008). MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Current Biology: CB, 18, 311-321.
28. Oka, T. V., et al. (2008). Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). Journal of Biological Chemistry, 283, 27534-27546.
29. Zhang, L., et al. (2008). The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Developmental Cell, 14, 377-387.
30. Wu, S., et al. (2008). The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Developmental Cell, 14(2008), 388-398.
31. Ziosi, M., et al. (2010). dMyc functions downstream of Yorkie to promote the supercompetitive behavior of hippo pathway mutant cells. PLoS Genetics, 6(9), e1001140. doi: 10.1371/journal.pgen.1001140.
32. Neto-Silva, R. M., et al. (2010). Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap. Developmental Cell, 19, 507-520.
33. Zhang, J., et al. (2009). YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nature Cell Biology, 11, 1444-1450.
34. Alarcon, C., et al. (2009). Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell, 139, 757-769.
35. Vitolo, M. I., et al. (2007). The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biology & Therapy, 6, 856-863.
36. Komuro, A., et al. (2003). WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. Journal of Biological Chemistry, 278, 33334-33341.
37. Strano, S., et al. (2001). Physical interaction with Yes-associated protein enhances p73 transcriptional activity. Journal of Biological Chemistry, 276, 15164-15173.
38. Lamar, J. M., et al. (2012). The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proceedings of the National Academy of Sciences of the United States of America, 109, E2441-E2450.
39. Xu, M. Z., et al. (2011). AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene, 30, 1229-1240.
40. Ehsanian, R., et al. (2010). YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene, 29, 6160-6171.
41. Yu,S.J., et al. (2013). MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clinical Cancer Research, 19, 1389-1399.
42. Espanel, X., et al. (2001). Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. Journal of Biological Chemistry, 276, 14514-14523.
43. Danovi, S. A., et al. (2008). Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis. Cell Death and Differentiation, 15, 217-219.
44. Levy, D., et al. (2008). Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Molecular Cell, 29, 350-361.
45. Levy, D., et al. (2007). The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death and Differentiation, 14, 743-751.
46. Okazaki, T., et al. (2012). Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma. Cancer Letters, 323, 199-207.
47. Yee, K.S., et al. (2012). A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Research, 72, 2206-2217.
48. Matallanas, D., et al. (2007). RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Molecular Cell, 27, 962-975.
49. Camargo, F. D., et al. (2007). YAP1 increases organ size and expands undifferentiated progenitor cells. Current Biology, 17(23), 2054-2060.
50. Lian, I., et al. (2010). The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes & Development, 24(11), 1106-1118.
51. Zhou, D., et al. (2011). Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proceedings of the National Academy of Sciences of the United States of America, 108(49), E1312-E1320.
52. Varelas, X., et al. (2010). The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Developmental Cell, 19, 831-844.
53. Yi, C., et al. (2010). Merlin in organ size control and tumorigenesis: hippo versus EGFR? Genes and Development, 24, 1673-1679.
54. Fan, R., et al. (2013). Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proceedings of the National Academy of Sciences of the United States of America, 110(7), 2569-2574.
55. Fernandez, L. A., et al. (2009). YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes and Development, 23, 2729-2741.
56. Tumaneng, K., et al. (2012). YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nature Cell Biology, 14, 1322-1329.
57. Rosenbluh, J., et al. (2012). â-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell, 151(7), 1457-1473.
58. Tschaharganeh, D. F., et al. (2013). Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology, 144(7), 1530-1542.
59. Muramatsu, T., et al. (2011). YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis, 32, 389-398.
60. Imoto, I., et al. (2001). Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Research, 61, 6629-6634.
61. Liu, T., et al. (2013). Clinical significance of yes-associated protein overexpression in cervical carcinoma: the differential effects based on histotypes. International Journal of Gynecological Cancer, 23, 735-742.
62. Tang, S.C., et al. (2002). BAG-1, an anti-apoptotic tumour marker. IUBMB Life, 53, 99-105.
63. Tang, S. C., et al. (1999). Expression of BAG-1 in invasive breast carcinomas. Journal of Clinical Oncology, 17, 1710-1719.
64. Turner, B. C., et al. (2001). BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. Journal of Clinical Oncology, 19, 992-1000.
65. Xu, M. Z., et al. (2009). Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer, 115, 4576-4585.
66. Song, M., et al. (2012). Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Research, 32, 3827-3834.
67. Wang, Y., et al. (2010). Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Science, 101, 1279-1285.
68. Su, L. L., et al. (2012). Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors. Chinese Medical Journal, 125, 4003-4008.
69. Carter, S. L., et al. (1994). Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Research, 54, 6270-6274.
70. Winqvist, R., et al. (1995). Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Research, 55, 2660-2664.
71. Gudmundsson, J., et al. (1995). Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. British Journal of Cancer, 72, 696-701.
72. Hampton, G. M., et al. (1994). Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Research, 54, 4586-4589.
73. Tomlinson, I. P., et al. (1995). Loss of heterozygosity on chromosome 11 q in breast cancer. Journal of Clinical Pathology, 48, 424-428.
74. Tufail, R., et al. (2012). Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Research and Treatment, 131, 743-750.
75. Wang, Y., et al. (2013). Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biology, 34(4), 2169-2174.
76. Fujii, M., et al. (2012). Exploration of a new drug that targets YAP. Journal of Biochemistry, 152(3), 209-211.
77. Bao, Y., et al. (2011). A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. Journal of Biochemistry, 150(2), 199-208.